The stock of Kintara Therapeutics Inc (KTRA) has seen a -18.14% decrease in the past week, with a 9.88% gain in the past month, and a -21.30% decrease in the past quarter. The volatility ratio for the week is 11.78%, and the volatility levels for the past 30 days are at 12.84% for KTRA. The simple moving average for the last 20 days is 0.07% for KTRA stock, with a simple moving average of -94.18% for the last 200 days.
Is It Worth Investing in Kintara Therapeutics Inc (NASDAQ: KTRA) Right Now?
Moreover, the 36-month beta value for KTRA is 0.53. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KTRA is 55.20M and currently, short sellers hold a 1.19% of that float. On April 16, 2024, KTRA’s average trading volume was 14.85M shares.
KTRA) stock’s latest price update
Kintara Therapeutics Inc (NASDAQ: KTRA)’s stock price has decreased by -11.99 compared to its previous closing price of 0.13. However, the company has seen a -18.14% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-04 that Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024.
KTRA Trading at 2.62% from the 50-Day Moving Average
After a stumble in the market that brought KTRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.16% of loss for the given period.
Volatility was left at 12.84%, however, over the last 30 days, the volatility rate increased by 11.78%, as shares surge +17.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.65% lower at present.
During the last 5 trading sessions, KTRA fell by -18.14%, which changed the moving average for the period of 200-days by -96.32% in comparison to the 20-day moving average, which settled at $0.1108. In addition, Kintara Therapeutics Inc saw -35.08% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KTRA
The total capital return value is set at -720.4. Equity return is now at value -329.00, with -179.36 for asset returns.
Currently, EBITDA for the company is -14.75 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
To wrap up, the performance of Kintara Therapeutics Inc (KTRA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
